The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920
(2003; 137 pages) View the PDF document
Table of Contents
View the document1. Introduction
View the document2. Open session
Open this folder and view contents3. Update on current activities
Close this folder4. Changes made in revising the Model List
Open this folder and view contents4.1 Applications for additions
Open this folder and view contents4.2 Applications for deletions
Close this folder4.3 Applications for addition of information
View the document4.3.1 Anti-leprosy medicines
Open this folder and view contents4.4 Other changes
Open this folder and view contents5. Reviews of sections of the Model List
View the document6. Priorities for future reviews
Open this folder and view contents7. Recommendations
View the documentReferences
View the documentAnnex 1 The 13th WHO Model List of Essential Medicines
View the documentAnnex 2 The Anatomical Therapeutic Chemical (ATC) classification system1
View the documentAlphabetical list of essential medicines (with ATC classification code numbers)
View the documentSelected WHO Publications of Related Interest

4.3.1 Anti-leprosy medicines

The Committee reviewed a request submitted by the Department of Communicable Diseases Prevention, Control and Eradication, WHO, to modify the Model List so as to better reflect the fact that anti-leprosy medicines should be used exclusively in combination (i.e. as multidrug therapy (MDT)) and be presented in colour-coded blister packs (i.e. MDT blister packs) in order to (i) prevent antimicrobial resistance, (ii) improve patient adherence to treatment and (iii) facilitate logistics and inventory control; and that MDT blister packs can be obtained free of charge through WHO.

To this end, the Committee recommended that the following text be inserted at the head of the appropriate section of the Model List (section 6.2.3 Antileprosy medicines):

Medicines used in the treatment of leprosy should never be used except in combination (i.e. as multidrug therapy (MDT)). Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (pauciba-cillary leprosy) or three-medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.

The Committee also recommended that the same information be included in the WHO Essential Medicines Library and the WHO model formulary.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017